BTIG Research Initiates Coverage On Avita Medical with Buy Rating, Announces $10 Price Target

BTIG Research analyst Ryan Zimmerman initiates coverage on Avita Medical (NASDAQ:RCEL) with a Buy rating and a $10 price target.